Log inTry free

Kodiak Sciences (KOD) stock

Market cap $2.0B

$94.80
+4.04%

After hours. Prices 19 minutes old, as of 7:07 PM ET. Members see real-⁠time prices.

Quality Score
12
Above Average
In its industry
#26of 276
Biotech
NextSep 2026 Trial data“Topline data for the one-year primary endpoint (Zenkuda and KSI-501) are expected in September 2026.”8-K, Aug 13
Cash$126M, about 3 quarters at the last year's spendingOn Jun 30 · the company says “into 2027”

Follow KOD's trial news. Members get an alert when Kodiak Sciences files news, and see its trials, share raises, and its CEO's filings.

Get an alert when KOD files news on its trialsFree for 24 hours.
Cash$126M, about 3 quarters at the last year's spendingOn Jun 30 · the company says “into 2027”
Pipeline and cash

What's next for KOD, and how long its cash lasts

From Kodiak Sciences’s SEC filings and ClinicalTrials.gov: the company’s own words and the arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

Sep 2026“Topline data for the one-year primary endpoint (Zenkuda and KSI-501) are expected in September 2026.”Trial data · 8-K, Aug 13

What it means: the first look at a trial’s main results, as the company reports them.

For members: 4 trials underway, 6 more milestones, and 19 filings.

Cash runway to Jun 30

About 3 quarters

$126M in cash ÷ $39.6M used a quarter over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's own estimate, which counts its plans, is “into 2027” (8-K, Aug 13).

For members: the share count, 1 raise, and the math.

Victor PerlrothChairman and CEOFrom their own Form 4 filings

For members: their 12 filings and quotes, and an alert each time they file.

Get an alert when KOD files news on its trialsFree for 24 hours.
Biotech dates

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first.

58 more companies with an FDA date or a trial due in these 60 days. Members see every one, with its score and cash runway, sorted by date.Get in free →
Quality Score

Why KOD scores 12

Above AverageTrending up, 8 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

Well above its own recent run. KOD scores 12 today, against a median of 1 over its last 20 recorded sessions.

  • +8Chart checks 8 of 14 firing right now, one point each
  • +3Long-term trend above a rising 200-⁠day average, near its 52-⁠week high
  • Run-up adds
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
  • Insider trades adds

No effect today: Size, Growth, Persistence, and News.

What every line is worth, and the reason behind it, on KOD and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 7:07 PM ET, at least 15 minutes behind. How we rank stocks.

Big story

Mon Sep 28: Trial

Kodiak Sciences Reports Positive Phase 3 DAYBREAK Results For Zenkuda And Tabirafusp-ted In WAMD

KOD closed +178.0% that day on 57.4x normal volume.

Reported by rttnews.com · covered by 2 outlets

Get an alert on KOD's next big story →

Outlet counts from the GDELT Project. The move is what KOD did that session, not a claim about why.

What's next

Expected to report Thu Nov 12, after the close

After its last 4 reports it closed +3.3% on average, higher 3 of 4 times.

What would move KOD's score: 7 things, for members

Alert me when KOD's Quality Score turns up

Free for 24 hours. No account needed.

For members

Here is what members see.

Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.

A member's scanner card for AMD: the Quality Score badge, the rank in the scan and in its industry, the chart checks bar, three plain lines on its strength, notable holders, and early signs, and pills for size, volume, RSI, and short interest
A card on the scanner, shown on AMD
A member's stock page for AMD: the Quality Score with its rank, the checks firing, and the reason behind it, the live price, and the chart
A stock page
The scanner a member sees: every stock as a card with its Quality Score, rank, and chart checks bar, the watchlist, and the day's top gainers
The scanner
The 14 checks

KOD has 8 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown
MA FAN21 EMAW.EMAHH/HL52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown
VOLVDUU/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown
ATR SQZSQUEEZENR7

The daily range is tight against its own recent history.

Buying1 of 3 shown
OBV+CLOSE HISPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on KOD, and all 14 on every stock.Get in free →
Its industry

How KOD ranks in Biotech

KOD is #26 of 276 by Quality Score. The top three are shown with their scores, and the rest by name.

More in Biotech, on the Healthcare page

Earnings

When does KOD report, and what happens after?

Expected to report Thu Nov 12, after the close (in 43 days). Not yet confirmed by the company.

ReportedGapReaction5 sessions
Aug 13, 2026After close-6.5%+3.4%-0.3%
May 7, 2026After close-3.7%-6.1%-11.4%
Mar 31, 2026After close+4.3%+12.3%+9.7%
Nov 13, 2025After close-2.3%+3.4%+3.8%

The gap is the next open against the close before the report; the reaction is where that session closed. KOD closed higher after 3 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

Filings

Who is trading KOD

Insiders

One insider bought $103M across 60 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyBaker Bros. Advisors Lp$17.7M10% ownerat $89.86 on Sep 28, filed today
All 60 insider filings on KOD from the last six months, for members.Get in free →

An insider has two business days to file a Form 4, so the trade is already days old when it becomes public. Shown as filed, with no delay.

See CEOs buying their own stock across the market

The company

About Kodiak Sciences

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

124 employeesPalo Alto, CAkodiak.com

For members

Every line of the score, on every stock.

  • Real-time prices, no delay
  • Every line of KOD's score, with the points and the reason
  • All 14 checks on KOD and on all 2,953 stocks
  • Every stock ranked, with the chart
  • Every filing, and optional alerts on KOD
BreakawaynowBaker Bros. Advisors Lp bought KOD$17.7M at $89.86, filed Sep 30

What a filing on KOD would have sent. Alerts are optional.

See all 14 checks on KODFree for 24 hours. No account needed.
Questions

Straight answers.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create your account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.